The changing epidemiology of meningococcal disease in the United States, 1992-1996

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1894-1901

  Rosenstein, Nancy E ^a   Perkins, Bradley A ^a   Stephens, David S ^d   Lefkowitz, Lewis ^e   Cartter, Matthew L ^f   Danila, Richard ^g,o   Cieslak, Paul ^h   Shutt, Kathleen A ^c   Popovic, Tanja ^a   Schuchat, Anne ^b   Harrison, Lee H ^i,j   Reingold, Arthur L ^k   Rothrock, G ^l   Mukerjee, N ^l   Daily, P ^l   Gelling, L ^l   Vugia, D ^l   Barnes, B ^e   Gilmore, C ^e   Farley, M ^d   Baughman, W ^d   Whitfield, S ^d   Bardsley, M ^d   Billmann, L ^p   Dwyer, D ^m   Hadler, J ⁿ   Mshar, P ⁿ   Barrett, N ⁿ   Morin, C ⁿ   Phan, Q ⁿ   Osterholm, M ^o   Rainbow, J ^o   Lexau, C ^o   Triden, L ^o   White, K ^o   Besser, J ^o   Stefonek, K ^h   Donegon, J ^h   Ladd Wilson, S ^h   Ajello, G ^p   Berkowitz, M ^p   Plikaytis, B ^p   Reeves, M ^p   Robinson, K ^p   Schmink, S ^p   Tondella, M L ^p   more..

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f Oregon Emerging Infections Program ^*  (United States)

^g MINNESOTA DEPARTMENT OF HEALTH   (United States)

^h Emerging Infections Program   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l California Emerging Infections Prog   (United States)

^m Maryland State Department of Health and Mental Hygiene   (United States)

ⁿ Minnesota Emerging Infections Prog ^*  (United States)

^o Minnesota Emerging Infections Program   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; FATALITY; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; PRIORITY JOURNAL; SEASONAL VARIATION; SEROTYPE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ELECTROPHORESIS; ENZYMES; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE; PREVALENCE; SEASONS; SEROTYPING; SEX DISTRIBUTION; UNITED STATES;

EID: 0032735120     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315158     Document Type: Article

References (41)

1. 1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970-6.
2. 2. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273:383-9.
3. 3. Woods CR, Rosenstein N, Perkins BA. Neisseria meningitidis outbreaks in the United States, 1994-97. In: Abstracts of the 38th annual meeting of the Infectious Diseases Society of America (Denver) [abstract 125FR]. Alexandria, VA: Infectious Diseases Society of America, 1998.
4. 4. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR Morb Mortal Wkly Rep 1993; 42:21-30.
5. 5. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs 1998; 55:347-66.
6. 6. Bisgard KM, Kao A, Leake JA, Strebel P, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998; 4:229-37.
7. 7. Twumasi PA, Kumah S, Leach A. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171:632-8.
8. 8. Campagne G, Garbar A, Fabre P, et al. Safety and immunogenicity of three doses of a N. meningitidis A/C diptheria conjugate vaccine in infants in Niger [abstract G-1]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:19.
9. 9. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children - a randomized controlled trial. JAMA 1996; 275:1499-503.
10. 10. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittam TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986; 51:873-84.
11. 11. Caugant DA, Mocca LF, Frasch CE, Froholm LO, Zollinger WD, Selander RK. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J Bacteriol 1987; 169:2781-92.
12. 12. Jacobs D. SAS/GRAPH software and numerical taxonomy. In: Proceedings of the 15th annual SAS Users Group International Conference (Nashville). Cary, NC: SAS Institute, 1990:1413-8.
13. 13. Wedege E, Froholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 1986; 51:571-8.
14. 14. Wedege E, Hoiby EA, Rosenqvist E, Froholm LO. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting, and ELISA. J Med Microbiol 1990; 31:195-201.
15. 15. Sacchi CT, Lemos AP, Whitney AM, Melles CE, Frasch CE, Mayer LW. Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system. Clin Diagn Lab Immunol 1998; 5:348-54.
16. 16. Rosenstein NE, Stocker SA, Popovic TA, et al. Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. Clin Infect Dis (in press).
17. 17. Schlech WF3, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. JAMA 1985; 253:1749-54.
18. 18. Centers for Disease Control and Prevention. Serogroup Y meningococcal disease - U.S. 1989 1996. MMWR Morb Mortal Wkly Rep 1996; 45: 1010-3.
19. 19. Koppes GM, Ellenbogen C, Gebhart RJ. Group Y meningococcal disease in United States Air Force recruits. Am J Med 1977; 62:661-6.
20. 20. Smilack JD. Group Y meningococcal disease. Twelve cases at an army training center. Ann Intern Med 1974; 81:740-5.
21. 21. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16:979-83.
22. 22. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990; 264:1271-5.
23. 23. Fischer M, Harrison L, Farley M, et al. Risk factors for sporadic meningococcal disease in North America. In: Abstracts of the 38th annual meeting of the Infectious Diseases Society of America (Denver) [abstract 552FR]. Alexandria, VA: Infectious Diseases Society of America, 1998.
24. 24. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol 1996; 143:624-30.
25. 25. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994; 32:323-30.
26. 26. Centers for Disease Control and Prevention. Trends in smoking initiation among adolescents and young adults United States, 1980-1989. MMWR Morb Mortal Wkly Rep 1995; 44:521-5.
27. 27. Saltzman RL, Peterson PK. Immunodeficiency of the elderly. Rev Infect Dis 1987; 9:1127-39.
28. 28. Arber S, Ginn J. Gender and inequalities in health in later life. Soc Sci Med 1993; 36:33-46.
29. 29. Centers for Disease Control and Prevention. Serogroup B meningococcal disease - Oregon, 1994. MMWR Morb Mortal Wkly Rep 1995; 44:121-4.
30. 30. Fischer M, Perkins BA. Neisseria meningitidis serogroup B: emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997; 8:50-6.
31. 31. Diermayer M, Hedberg K, Hoesly FC, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-7.
32. 32. Wyle FA, Artenstein MS, Brandt BL, et al. Immunological response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126: 514-22.
33. 33. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
34. 34. Sierra GVG, Campo HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-210.
35. 35. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-8.
36. 36. Zollinger WD, Boslego J, Moran E. Meningococcal serogroup b vaccine protein trial and follow-up studies. NIPH Ann 1991; 14:211-3.
37. 37. Noah N, Connolly M. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993 6. European Meningitis Surveillance Group. Epidemiol Infect 1999; 122:41-9.
38. 38. Raymond NJ, Reeves M, Ajello G, et al. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. J Infect Dis 1997; 176: 1277-84.
39. 39. Kirsch EA, Barton RP, Kitcahen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996; 15:967-79.
40. 40. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998; 117:497-500.
41. 41. Quagliarello V, Scheid M. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708-16.